Sartorius AG

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 15.1B. In comparison, PHIA.DE has a market cap of 43.4B. Regarding current trading prices, SRT3.DE is priced at €218.80, while PHIA.DE trades at €48.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 93.50, whereas PHIA.DE's P/E ratio is 13.73. In terms of profitability, SRT3.DE's ROE is +0.06%, compared to PHIA.DE's ROE of +0.08%. Regarding short-term risk, SRT3.DE is more volatile compared to PHIA.DE. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.Check PHIA.DE's competition here

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 15.1B. In comparison, BTL.DE has a market cap of 29.6B. Regarding current trading prices, SRT3.DE is priced at €218.80, while BTL.DE trades at €58.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 93.50, whereas BTL.DE's P/E ratio is 30.31. In terms of profitability, SRT3.DE's ROE is +0.06%, compared to BTL.DE's ROE of -0.08%. Regarding short-term risk, SRT3.DE is more volatile compared to BTL.DE. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.Check BTL.DE's competition here

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 15.1B. In comparison, SRT.DE has a market cap of 12.1B. Regarding current trading prices, SRT3.DE is priced at €218.80, while SRT.DE trades at €175.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 93.50, whereas SRT.DE's P/E ratio is 74.47. In terms of profitability, SRT3.DE's ROE is +0.06%, compared to SRT.DE's ROE of +0.06%. Regarding short-term risk, SRT3.DE is less volatile compared to SRT.DE. This indicates potentially lower risk in terms of short-term price fluctuations for SRT3.DE.Check SRT.DE's competition here

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 15.1B. In comparison, FIE.DE has a market cap of 3.7B. Regarding current trading prices, SRT3.DE is priced at €218.80, while FIE.DE trades at €44.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 93.50, whereas FIE.DE's P/E ratio is 20.53. In terms of profitability, SRT3.DE's ROE is +0.06%, compared to FIE.DE's ROE of +0.20%. Regarding short-term risk, SRT3.DE is more volatile compared to FIE.DE. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.Check FIE.DE's competition here

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 15.1B. In comparison, AFX.DE has a market cap of 2.3B. Regarding current trading prices, SRT3.DE is priced at €218.80, while AFX.DE trades at €26.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 93.50, whereas AFX.DE's P/E ratio is 16.42. In terms of profitability, SRT3.DE's ROE is +0.06%, compared to AFX.DE's ROE of +0.07%. Regarding short-term risk, SRT3.DE is more volatile compared to AFX.DE. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.Check AFX.DE's competition here

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 15.1B. In comparison, 1SXP.F has a market cap of 2.3B. Regarding current trading prices, SRT3.DE is priced at €218.80, while 1SXP.F trades at €15.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 93.50, whereas 1SXP.F's P/E ratio is 15.17. In terms of profitability, SRT3.DE's ROE is +0.06%, compared to 1SXP.F's ROE of +0.17%. Regarding short-term risk, SRT3.DE is more volatile compared to 1SXP.F. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.Check 1SXP.F's competition here

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 15.1B. In comparison, MYD.DE has a market cap of 2.2B. Regarding current trading prices, SRT3.DE is priced at €218.80, while MYD.DE trades at €26.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 93.50, whereas MYD.DE's P/E ratio is -256.92. In terms of profitability, SRT3.DE's ROE is +0.06%, compared to MYD.DE's ROE of -0.16%. Regarding short-term risk, SRT3.DE is more volatile compared to MYD.DE. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.Check MYD.DE's competition here

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 15.1B. In comparison, DY2.F has a market cap of 2B. Regarding current trading prices, SRT3.DE is priced at €218.80, while DY2.F trades at €10.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 93.50, whereas DY2.F's P/E ratio is -3.98. In terms of profitability, SRT3.DE's ROE is +0.06%, compared to DY2.F's ROE of -0.48%. Regarding short-term risk, SRT3.DE is more volatile compared to DY2.F. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.Check DY2.F's competition here

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 15.1B. In comparison, 2B4.F has a market cap of 1.4B. Regarding current trading prices, SRT3.DE is priced at €218.80, while 2B4.F trades at €21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 93.50, whereas 2B4.F's P/E ratio is 86.32. In terms of profitability, SRT3.DE's ROE is +0.06%, compared to 2B4.F's ROE of +0.22%. Regarding short-term risk, SRT3.DE is more volatile compared to 2B4.F. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.Check 2B4.F's competition here

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 15.1B. In comparison, GXI.DE has a market cap of 828.3M. Regarding current trading prices, SRT3.DE is priced at €218.80, while GXI.DE trades at €23.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 93.50, whereas GXI.DE's P/E ratio is 35.26. In terms of profitability, SRT3.DE's ROE is +0.06%, compared to GXI.DE's ROE of +0.02%. Regarding short-term risk, SRT3.DE is less volatile compared to GXI.DE. This indicates potentially lower risk in terms of short-term price fluctuations for SRT3.DE.Check GXI.DE's competition here

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 15.1B. In comparison, MF6.DE has a market cap of 3.5M. Regarding current trading prices, SRT3.DE is priced at €218.80, while MF6.DE trades at €0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 93.50, whereas MF6.DE's P/E ratio is 0.25. In terms of profitability, SRT3.DE's ROE is +0.06%, compared to MF6.DE's ROE of -0.34%. Regarding short-term risk, SRT3.DE is less volatile compared to MF6.DE. This indicates potentially lower risk in terms of short-term price fluctuations for SRT3.DE.Check MF6.DE's competition here